Retatrutide Stack

The Retatrutide Stack is the most aggressive fat loss protocol in the peptide community, combining the triple-agonist GLP-1/GIP/glucagon receptor action of Retatrutide with Tesamorelin''s specific visceral fat reduction and GH-axis support. Retatrutide is a next-generation incretin-based peptide that activates three distinct metabolic receptors simultaneously: GLP-1 (appetite suppression and glucose regulation), GIP (enhanced fat metabolism and insulin sensitivity), and glucagon (direct fat mobilization and energy expenditure increase). Phase 2 clinical trials showed Retatrutide produced up to 24% total body weight reduction — the most powerful weight loss signal observed in any pharmaceutical compound to date. It remains investigational (not FDA-approved) at time of writing. Tesamorelin is the only FDA-approved growth hormone secretagogue, originally approved for HIV-related lipodystrophy (excess visceral fat). It is a GHRH analog that specifically targets visceral adipose tissue — the metabolically dangerous abdominal fat. By stimulating GH release, Tesamorelin drives lipolysis specifically in visceral fat depots while preserving lean muscle mass. This makes it an ideal complement to Retatrutide''s systemic fat mobilization. The combination targets fat loss through three independent mechanisms: appetite and glucose regulation (Retatrutide''s GLP-1 action), enhanced fat metabolism (Retatrutide''s GIP action), direct energy expenditure increase (Retatrutide''s glucagon action), and GH-driven visceral lipolysis (Tesamorelin). Together, the stack addresses both the appetite and metabolic sides of obesity while specifically targeting visceral fat — the most dangerous and most resistant-to-diet depot. Requires close medical supervision due to the potency of both compounds.